Pharmacological effects of polydatin in the treatment of metabolic diseases: A review

• Published in: Phytomedicine (Stuttgart) Vol. 102; p. 154161
• Main Authors: Luo, Jinli, Chen, Shuo, Wang, Li, Zhao, Xiaohua, Piao, Chunli
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 20.07.2022
• Subjects: AMP-Activated Protein Kinases; Atherosclerosis; Diabetes; Diabetes Mellitus; Glucosides - pharmacology; Glucosides - therapeutic use; Gout; Humans; Metabolic disease; NAFLD; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - metabolism; Obesity - drug therapy; Phosphatidylinositol 3-Kinases; Polydatin; Quality of Life; Stilbenes; CRP; FFA; T2DM; NAFLD; CPP; MCP-1; LDL-C; Gout; FN; TGF-b1; DN; ICAM-1; IDF; UA; Metabolic disease; HDL-C; LDH; MD; STZ; HUVEC; TLR; LDLR; Polydatin; WHO; ABCA1; GSH-Px; GLUT; SOD; Akt; IL-1β; NASH; AEGs; MSU; TC; HOMA-IR; AS; TG; PD; TNF-α; PBEF; GSIS; ROS; AMPK; SGLT; Diabetes; VSMC; TCM
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2022.154161

Metabolic diseases (MDs), a series of chronic disorders, severely decreases the quality of life for patients but also cause a heavy economic burden. Emerging evidence suggests that Polydatin (PD), an important glucoside of resveratrol, is widely distributed in many plants and has shown good therapeutic potential in metabolic diseases. To review the PD discovered before 2021 and their potential to treat metabolic diseases. The activities against diabetes, Obesity, atherosclerosis, NAFLD, NASH, hyperlipidemia, and gout with special emphasis on pharmacology, pharmacokinetics, mechanisms of action, possible roles in current medicine, and future perspectives are discussed. A comprehensive search of published literature was conducted to locate original publications pertaining to polydatin and MDs through the end of 2021 using MEDLINE, Elsevier, Springer, PubMed, Scholar, and CNKI databases. The main inquiry used was for the presence of the following keywords in various combinations in the abstracts: 'Polydatin', 'Metabolic diseases', 'Pharmacology', ‘Toxicology’, 'Pharmacokinetics', 'Diabetes', 'Obesity', 'Atherosclerosis', 'Non-alcoholic fatty liver disease', 'Non‐alcoholic steatohepatitis', 'Hyperlipidemia', and 'Gout'. The search yielded 987 articles, of which 33 articles were included in this review. Studies have revealed that PD can promote insulin secretion, alleviate insulin resistance, regulate glucose and lipid metabolism, reduce liver lipid deposition, inhibit inflammation, oxidative stress, and decrease uric acid deposition in preclinical experiments. The underlying mechanisms of PD in treatment MDs may be attributed to the regulation of multiple signaling pathways, including. NF-κB, AGEs/RAGE, MAPK/ERK, AMPK/LDLR, IRS1/PI3K/AKT, LKB1/AMPK, PPARβ-NO, SIRT1-PGC-1α-SOD2, PKC, etc., The pharmacokinetic profiles of PD provide valuable information on therapeutic efficacy in treating metabolic diseases. This review summarizes the available reports and evidence which support the use of PD as a potential candidate in the treatment of MDs and provides an overview of the modulatory effects of PD in metabolic diseases and cell signaling pathways, which may have important implications in its future clinical use. [Display omitted]